Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. The initial ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $51.6, a high estimate of $64.00, and a low estimate of $39.00. A decline of 4.44% from the ...

He emphasized that residential investment will be crucial for overall GDP growth, as current CapEx spending in the US is ...

Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582.

Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), a pharmaceutical company with a market capitalization of $5.85 billion, announced the results of its annual stockholders meeting held on June 5, 2025 ...

Ionis Pharmaceuticals announced Dr. Holly Kordasiewicz will rise to assume the role of chief development officer in January 2026. Kelsey Fleury was promoted to SVP of paid media at GCI Health, a 2025 ...

The 7MM Polycythemia Vera market size reached approximately USD 2 billion in 2024 and is projected to grow significantly through 2034. Key players such as Incyte, PharmaEssentia, Protagonist ...